The (6;9) chromosomal translocation is associated with acute myelogenousleukemia (AML) and fuses the dek and can genes. This results in expression of the oncogenic DEK-CAN fusion protein, consisting of the N-terminal two-thirds of DEK and the C-terminal two-thirds of CAN. Although, on its own, DEK exhibits anti-oncogenic properties, the DEK-CAN chimera appears to be oncogenic. DEK is a nuclear protein with a calculated molecular weight of 42-43 kD, that can be observable at 50 kD, and reportedly exhibits no substantial homology to any known protein sequences. Although it contains 42% charged amino acids and multiple acidic sequences, specific structural features have yet to be identified. In addition to its involvement in AML, DEK is associated with several disease states, such as juvenile rheumatoid arthritis where it is an autoantigen. Efforts to define the cellular function of DEK led to its identification as the pets factor. The peri-ets (pets) site is a TG-rich element between the two Elf-1 binding sites of the HIV-2 enhancer. The pets site mediates transcriptional activation in response to T cell stimulation. Thus, DEK is a site-specific DNA binding protein that functions in transcriptional regulation and signal transduction.
This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.